Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Cancer. 2012 Nov 6;119(5):1089–1097. doi: 10.1002/cncr.27835

Figure 3.

Figure 3

Percent of patients receiving RT who were treated with 2-dimensional or 3-dimensional RT in the last 12 months of life after a metastatic cancer diagnosis. (Cochrane Armitage tests of trend, p<0.0001 for both curves). The receipt of 2D-RT and 3D-RT are not mutually exclusive.